Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSGLC): A phase III prospective randomised trial of the Italian oncology group for clinical research (GOIRC)

European Journal of Cancer

Volumn 34, Issue 12, 1998, Pages 1974-1976

  Boni, C ^a   Savoldi, L ^a   Bisagni, G ^a   Ceci, G ^b   Crino L ^d   De Lisi, V ^b   Di Costanzo, F ^c   Lasagni, L ^a   Manenti, A L ^a   Moretti, G ^a   Rondini, E ^a   Sassi, M ^a   Zadro, A ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

^c S MARIA HOSPITAL   (Italy)

^d NONE

Author keywords

Cisplatin; Continuous infusion; MVP; Non small cell lung cancer; Randomised phase III study

Indexed keywords

CISPLATIN; MITOMYCIN C; VINDESINE;

ADULT; AGED; ANEMIA; ARTICLE; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG INFUSION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCINS; PROSPECTIVE STUDIES; VINDESINE;

EID: 0032212307     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00231-7     Document Type: Article

References (10)

1. 1. Kris MG, Gralla RJ, Wertheim MS, et al. Trial of the combination of mitomycin, vindesine and cisplatin in patients with advanced non-small cell lung cancer. Cancer Treat Rep 1986, 70, 1091-1096.
2. 2. Crinò L, Clerici M, Figoli F, et al. Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol 1995, 6, 347-353.
3. 3. De Conti RC, Toftness BR, Lange RC. Clinical and pharmacological studies with cis-dichlorodiammineplatinum (II). Cancer Res 1973, 33, 1310-1315.
4. 4. Salem P, Khalyl M, Jabboury K, Hashimi L. Cis-diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity. Cancer 1984, 53, 837-840.
5. 5. Salem PA, Hall SW, Benjamin RS, et al. Clinical phase I-II study of cis-dichlorodiammineplatinum (II) given by continuous i.v. infusion. Cancer Treat Rep 1978, 62, 1553-1555.
6. 6. Posner MR, Skarin AT, Clark J, Ervin TJ. Phase I study of continuous infusion cisplatin. Cancer Treat Rep 1986, 70, 847-850.
7. 7. Bernal AG, Cruz JJ, Sanchez P, et al. Four-day continuous infusion of cisplatin and 5-fluorouracil in head and neck cancer. Cancer 1989, 63, 1927-1930.
8. 8. Drewinko B, Brown BW, Gottlieb JA. The effect of cis-diamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implication. Cancer Res 1973, 33, 3091-3095.
9. 9. Simgestad CP, Gardina DJ, Peters LJ. Cell cycle phase preferential killing of fibrosarcoma tumor cells by cis-dichlorodiammineplatinum or adriamycin. Proc Am Assoc Cancer Res 1979, 20, 178.
10. 10. Boni C, Moretti G, Savoldi L, et al. Neoadjuvant chemotherapy with continuous infusion of cisplatin and fluorouracil in stage II-IV, M0 squamous cell carcinoma of the head and neck. Tumori 1996, 82, 567-572.